Suppr超能文献

吸入用二丙酸倍氯米松与茶碱治疗妊娠期中度哮喘的随机试验

Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy.

作者信息

Dombrowski Mitchell P, Schatz Michael, Wise Robert, Thom Elizabeth A, Landon Mark, Mabie William, Newman Roger B, McNellis Donald, Hauth John C, Lindheimer Marshall, Caritis Steve N, Leveno Kenneth J, Meis Paul, Miodovnik Menachem, Wapner Ronald J, Varner Michael W, O'Sullivan Mary Jo, Conway Deborah L

机构信息

Department of Obstetrics and Gynecology, Wayne State University, Detroit, Mich, USA.

出版信息

Am J Obstet Gynecol. 2004 Mar;190(3):737-44. doi: 10.1016/j.ajog.2003.09.071.

Abstract

OBJECTIVE

This study was undertaken to compare the efficacy of inhaled beclomethasone dipropionate to oral theophylline for the prevention of asthma exacerbation(s) requiring medical intervention.

STUDY DESIGN

A prospective, double-blind, double placebo-controlled randomized clinical trial of pregnant women with moderate asthma was performed.

RESULTS

There was no significant difference (P=.554) in the proportion of asthma exacerbations among the 194 women in the beclomethasone cohort (18.0%) versus the 191 in the theophylline cohort (20.4%; risk ratio [RR]=0.9, 95% CI=0.6-1.3). The beclomethasone cohort had significantly lower incidences of discontinuing study medications caused by side effects (RR=0.3, 95% CI=0.1-0.9; P=.016), and proportion of study visits with forced expiratory volume expired in 1 second (FEV1) less than 80% predicted (0.284+/-0.331 vs 0.284+/-0.221, P=.039). There were no significant differences in treatment failure, compliance, or proportion of peak expiratory flow rate less than 80% predicted. There were no significant differences in maternal or perinatal outcomes.

CONCLUSION

The treatment of moderate asthma with inhaled beclomethasone versus oral theophylline resulted in similar rates of asthma exacerbations and similar obstetric and perinatal outcomes. These results favor the use of inhaled corticosteroids for moderate asthma during pregnancy because of the improved FEV1 and because theophylline had more side effects and requires serum monitoring.

摘要

目的

本研究旨在比较吸入丙酸倍氯米松与口服茶碱预防需要医疗干预的哮喘发作的疗效。

研究设计

对患有中度哮喘的孕妇进行了一项前瞻性、双盲、双安慰剂对照的随机临床试验。

结果

倍氯米松组194名女性中哮喘发作的比例(18.0%)与茶碱组191名女性中哮喘发作的比例(20.4%)相比,无显著差异(P = 0.554;风险比[RR]=0.9,95%置信区间[CI]=0.6 - 1.3)。倍氯米松组因副作用导致停用研究药物的发生率显著较低(RR = 0.3,95% CI = 0.1 - 0.9;P = 0.016),且1秒用力呼气容积(FEV1)低于预测值80%的研究访视比例也较低(0.284±0.331对0.284±0.221,P = 0.039)。在治疗失败、依从性或呼气峰值流速低于预测值80%的比例方面无显著差异。在孕产妇或围产期结局方面也无显著差异。

结论

吸入倍氯米松与口服茶碱治疗中度哮喘导致哮喘发作率相似,产科和围产期结局也相似。由于FEV1有所改善,且茶碱有更多副作用且需要血清监测,这些结果支持在孕期使用吸入性糖皮质激素治疗中度哮喘。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验